A Gaylord King is a notable inventor based in Bartonville, TX (US). He has made significant contributions to the field of radioimmunoconjugates, which are crucial in the development of targeted cancer therapies. His innovative work has led to the creation of a unique patent that enhances the efficacy of monoclonal antibodies in medical applications.

Latest Patents

King holds a patent for "Methods for generating radioimmunoconjugates." This patent details methods for generating an Ac-225 radioconjugate comprising a monoclonal antibody (mAb) (IgG). The specific radioimmunoconjugate he developed is an [Ac-225]-p-SCN-Bn-DOT AIHuM195 radioimmunoconjugate. This advancement represents a significant step forward in the field of targeted cancer treatment.

Career Highlights

A Gaylord King is currently associated with Actinium Pharmaceuticals, Limited, where he continues to work on innovative solutions in the pharmaceutical industry. His expertise in radioimmunoconjugates has positioned him as a key player in the development of new therapeutic strategies.

Collaborations

King collaborates with talented professionals in his field, including Jaime Simon and Josue Manuel Moreno Bermudez. These partnerships enhance the research and development efforts at Actinium Pharmaceuticals, Limited.

Conclusion

A Gaylord King is a pioneering inventor whose work in radioimmunoconjugates is paving the way for advancements in cancer treatment. His contributions are vital to the ongoing evolution of targeted therapies in medicine.

Profile summary based on public USPTO records.